Arvinas (ARVN) Cash & Equivalents (2017 - 2026)
Arvinas (ARVN) recorded Cash & Equivalents of $94.3 million in Q2 2026, down 17.9% from $114.9 million a year earlier but up 8.0% from the prior quarter.
Arvinas (ARVN) Cash & Equivalents (2017 - 2026) Analysis & Trends
At the end of FY2025, Arvinas reported Cash & Equivalents of $142.9 million, up 42.2% from FY2024.
- Annual Cash & Equivalents has a five-year compound annual growth rate of -24.7% (FY2020 to FY2025).
- Across earlier years, Cash & Equivalents came in at $100.5 million in FY2024 (-67.8%), $311.7 million in FY2023 (+283.4%), $81.3 million in FY2022 (-24.9%) and $108.3 million in FY2021 (-81.6%).
- Quarterly Cash & Equivalents has ranged from $62.3 million in Q1 2022 to $311.7 million in Q4 2023 over the past five years.
- On a year-over-year basis, Cash & Equivalents rose in three of the last eight quarters, with an average decline of 9.4%.
- Peak year-over-year performance for Cash & Equivalents in the last five years was growth of 283.4% in Q4 2023, against a decline of 82.0% in Q1 2022 at the low end.
- Per Business Quant, the preceding three quarters came in at $87.3 million (Q1 2026), $142.9 million (Q4 2025) and $101.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Arvinas | 483.87 Mn | -2.17 Bn | - | 94.30 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 94.30 Mn |
| Mar 31, 2026 | 87.30 Mn |
| Dec 31, 2025 | 142.90 Mn |
| Sep 30, 2025 | 101.50 Mn |
| Jun 30, 2025 | 114.90 Mn |
| Mar 31, 2025 | 81.00 Mn |
| Dec 31, 2024 | 100.50 Mn |
| Sep 30, 2024 | 85.20 Mn |
| Jun 30, 2024 | 154.80 Mn |
| Mar 31, 2024 | 88.00 Mn |
| Dec 31, 2023 | 311.70 Mn |
| Sep 30, 2023 | 113.70 Mn |
| Jun 30, 2023 | 90.60 Mn |
| Mar 31, 2023 | 130.20 Mn |
| Dec 31, 2022 | 81.30 Mn |
| Sep 30, 2022 | 132.60 Mn |
| Jun 30, 2022 | 93.20 Mn |
| Mar 31, 2022 | 62.30 Mn |
| Dec 31, 2021 | 108.30 Mn |
| Sep 30, 2021 | 255.66 Mn |
Arvinas Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=ARVN&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "ARVN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=ARVN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();